TNF and pneumocystosis: Anti-TNFα (Infliximab, etanercept, or adalimumab) would also have a limited impact on PCP development [98,99,100], In this context, the PCP risk seems to be mostly associated with another concomitant immunosuppressant factor such as glucocorticoids or with an impact of anti-TNFα on TCD4 [101].